December 14, 2012

HELIX BIOPHARMA AND MERCK TERMINATE MATERIAL TRANSFER AND LICENSE OPTION AGREEMENT FOR TOPICAL INTERFERON ALPHA-2B DEVELOPMENT PROGRAM (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing
drug candidates for the prevention and treatment of cancer, today announced that Helix and Merck, known as
MSD outside the United States and Canada, have agreed to terminate their collaboration under the Material
Transfer and License Option Agreement, originally entered into between Helix and a Merck subsidiary in
December 2000, for the development of pharmaceutical products containing Topical Interferon Alpha-2b
(“TIFN alpha-2b”).